Articles, guides, and regulatory updates from our community.
A landmark 2025 BMJ network meta-analysis comparing 19 obesity drugs across 262 trials reveals key trade-offs between weight loss, side effects, and heart health.
By Peptide Association Research Team
A landmark 2026 BMJ network meta-analysis of 262 trials compares 19 obesity drugs. See what researchers found about weight loss, harms, and cardiovascular outcomes.
By Peptide Association Research Team
A major 2026 BMJ network meta-analysis compared 19 obesity drugs across 262 trials. See what the evidence shows about benefits, harms, and trade-offs.
By Peptide Association Research Team
A major 2025 BMJ network meta-analysis compared 19 obesity drugs across 262 trials. See what researchers found about benefits, risks, and tradeoffs.
By Peptide Association Research Team
A major 2025 BMJ network meta-analysis of 262 trials compares 19 obesity drugs on weight loss, safety, and cardiovascular outcomes. Here's what patients should know.
By Peptide Association Research Team
A 2026 NIDDK workshop study examines how real-world evidence can fill critical gaps in GLP-1 receptor agonist safety, effectiveness, and coverage decisions.
By Peptide Association Research Team
New research reveals how diabetes silently damages heart blood vessels and nerve signaling—raising alarms about undetected cardiac risk in diabetic patients.
By Peptide Association Research Team
A 2026 review in JBJS Reviews examines the evidence, safety, and antidoping implications of injectable peptides used in sports medicine and orthopaedics.
By Peptide Association Research Team
A 2026 structured review examines injectable peptides for musculoskeletal recovery. Learn what the evidence, safety data, and antidoping rules mean for athletes.
By Peptide Association Research Team